Johnson & Johnson shares trade near their 52-week high after a 55% rise, driven by strong revenue growth and promising drug sales. The company raised its full-year guidance, highlighting growth in key products like DARZALEX and TREMFYA. However, the stock's high valuation, recent earnings challenges, and ongoing litigation suggest caution. Analysts recommend holding the stock, waiting for clearer catalysts or a price pullback before buying more, as most positive news is already priced in.
Three dividend stocks—Johnson & Johnson, Realty Income, and JPMorgan Chase—are highlighted as strong retirement investments due to their reliable and growing payouts. Johnson & Johnson boasts a 64-year streak of dividend increases supported by accele...
PepsiCo announced that Joaquin Duato, Chairman and CEO of Johnson & Johnson, will join its Board of Directors as an independent member effective December 1, 2026. Duato will serve on the Audit Committee, bringing over three decades of leadership expe...
